Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Genentech

< Previous 1 2 Next >
Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis
From Genentech
Via Business Wire
Tickers RHHBY
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
From Genentech
Via Business Wire
Tickers RHHBY
New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting
From Genentech
Via Business Wire
Tickers RHHBY
FDA Approves Genentech’s Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Data Highlights Strength of Ophthalmology Portfolio and Commitment to Advancing Eye Care at ARVO 2023
From Genentech
Via Business Wire
Tickers RHHBY
New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
Tickers RHHBY
FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
From Genentech
Via Business Wire
Tickers RHHBY
New Phase III Data Show Genentech’s Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People With Retinal Vein Occlusion (RVO)
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial
From Genentech
Via Business Wire
Tickers RHHBY
FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma
From Genentech
Via Business Wire
Tickers RHHBY
FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma
From Genentech
Via Business Wire
Tickers RHHBY
FDA Approves Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022
From Genentech
Via Business Wire
Tickers RHHBY
Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Provides Update on Phase III GRADUATE Program Evaluating Gantenerumab in Early Alzheimer’s Disease
From Genentech
Via Business Wire
Tickers RHHBY
Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs
From Genentech
Via Business Wire
Tickers RHHBY
Positive Topline Phase III Results Show Genentech’s Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO)
From Genentech
Via Business Wire
Tickers RHHBY
Early Treatment With Genentech’s Ocrevus (ocrelizumab) Leads to Reduced Disease Progression and Healthcare Costs; Nine-Year Safety Data Reinforce Favorable Benefit-Risk Profile
From Genentech
Via Business Wire
Tickers RHHBY
Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research Into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022
From Genentech
Via Business Wire
Tickers RHHBY
Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
Tickers RHHBY
FDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results
From Genentech
Via Business Wire
Tickers RHHBY
Genentech to Present Scientific Progress Across Alzheimer’s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting
From Genentech
Via Business Wire
Tickers RHHBY
New Two-Year Data Confirm Genentech’s Vabysmo Improves Vision With Fewer Treatments for People With Wet Age-Related Macular Degeneration
From Genentech
Via Business Wire
Tickers RHHBY
New Data From Phase III HAVEN 6 Study Reinforce Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A
From Genentech
Via Business Wire
Tickers RHHBY
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.